Suppr超能文献

中国产植入体(II型)使用第一年的有效性、安全性及可接受性:来自肯尼亚和巴基斯坦的结果。

Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: results from Kenya and Pakistan.

作者信息

Lendvay Anja, Otieno-Masaba Rose, Azmat Syed Khurram, Wheeless Angie, Hameed Waqas, Shaikh Babar Tasneem, Kuria Shiphrah, Steiner Markus J, Chen Mario, Feldblum Paul J

机构信息

FHI 360, Durham, NC 27713, USA.

FHI 360, Nairobi, Kenya.

出版信息

Contraception. 2014 Mar;89(3):197-203. doi: 10.1016/j.contraception.2013.11.002. Epub 2013 Nov 12.

Abstract

BACKGROUND

Sino-implant (II) is a two-rod subcutaneous contraceptive implant used up to 4 years, containing 150 mg of levonorgestrel. We conducted two observational studies of Sino-implant (II) to evaluate its performance in routine service delivery settings.

METHODS

We enrolled 1326 women age 18-44 who had Sino-implant (II) inserted at clinics in Pakistan and Kenya. Women were followed-up using either an active or passive follow-up scheme in each study. Study outcomes were: one-year cumulative pregnancy and discontinuation rates; rates of insertion and removal complications; adverse event and side effect rates; reasons for discontinuation; and implant acceptability and satisfaction with clinic services.

RESULTS

A total of 754 women returned for at least one follow-up visit. The overall Pearl pregnancy rate was 0.4 per 100 woman-years [95% confidence interval (CI) 0.1, 0.9] resulting from 1 confirmed post-insertion pregnancy in Kenya and 4 in Pakistan. Country-specific Pearl rates were 0.2 (95% CI 0.0, 0.9) in Kenya and 0.6 (95% CI 0.2, 1.6) in Pakistan. The total cumulative 12-month probability of removal was 7.6% (95% CI 6.1, 9.1), with country-specific removal probabilities of 3.7% in Kenya (95% CI 2.1, 5.3) and 10.8% in Pakistan (95% CI 8.5, 13.2). Four serious adverse events occurred in Kenya and none occurred in Pakistan; one SAE (an ectopic pregnancy) was possibly related to Sino-implant (II). Most women in both countries said they would recommend the implant to others.

CONCLUSION

The results from these studies reveal high effectiveness and favorable safety and acceptability during the first year of use of Sino-implant.

IMPLICATION

The favorable Sino-implant (II) findings from Kenya and Pakistan provide further evidence from disparate regions that Sino-implant (II) is safe, effective and acceptable during routine service delivery.

摘要

背景

欣妈富隆(II)是一种含150毫克左炔诺孕酮的双棒皮下避孕植入剂,使用期限长达4年。我们开展了两项关于欣妈富隆(II)的观察性研究,以评估其在常规服务提供环境中的表现。

方法

我们招募了1326名年龄在18至44岁之间、在巴基斯坦和肯尼亚的诊所植入欣妈富隆(II)的女性。在每项研究中,采用主动或被动随访方案对女性进行随访。研究结果包括:一年累积妊娠率和停用率;植入和取出并发症发生率;不良事件和副作用发生率;停用原因;以及植入剂的可接受性和对诊所服务的满意度。

结果

共有754名女性返回进行了至少一次随访。总Pearl妊娠率为每100妇女年0.4例[95%置信区间(CI)0.1,0.9],这是由于肯尼亚有1例确诊的植入后妊娠,巴基斯坦有4例。肯尼亚和巴基斯坦的国别Pearl率分别为0.2(95%CI 0.0,0.9)和0.6(95%CI 0.2,1.6)。12个月累计取出概率为7.6%(95%CI 6.1,9.1),肯尼亚和巴基斯坦的国别取出概率分别为3.7%(95%CI 2.1,5.3)和10.8%(95%CI 8.5,13.2)。肯尼亚发生了4起严重不良事件,巴基斯坦未发生;1起严重不良事件(异位妊娠)可能与欣妈富隆(II)有关。两国的大多数女性表示,她们会向其他人推荐该植入剂。

结论

这些研究结果显示,欣妈富隆在使用的第一年具有高效性、良好的安全性和可接受性。

启示

来自肯尼亚和巴基斯坦的欣妈富隆(II)的良好研究结果为不同地区提供了进一步的证据,表明欣妈富隆(II)在常规服务提供过程中是安全、有效且可接受的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验